International Clinical Psychopharmacology最新文献

Diabetes mellitus in patients with chronic bipolar disorder: prevalence, clinical correlates and relationship with homocysteine.

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-03-01 Epub Date: 2023-11-20 DOI: 10.1097/YIC.0000000000000504

Li Mu, Dachun Chen, Meihong Xiu, Huixia Zhou, Dongmei Wang, Xiang-Yang Zhang

{"title":"Diabetes mellitus in patients with chronic bipolar disorder: prevalence, clinical correlates and relationship with homocysteine.","authors":"Li Mu, Dachun Chen, Meihong Xiu, Huixia Zhou, Dongmei Wang, Xiang-Yang Zhang","doi":"10.1097/YIC.0000000000000504","DOIUrl":"https://doi.org/10.1097/YIC.0000000000000504","url":null,"abstract":"Comorbid diabetes mellitus in patients with bipolar disorder may contribute to increased morbidity and mortality. To determine the prevalence of diabetes mellitus in bipolar disorder patients and its clinico-demographic and homocysteine correlates, we conducted a cross-sectional survey of 195 bipolar disorder inpatients. They received questionnaires, clinical measurements and laboratory tests to assess demographic characteristics, anthropometric variables, clinical variables and plasma homocysteine levels. The prevalence of diabetes mellitus (including type 1, type 2 and special types) in Chinese bipolar disorder patients was 14.9%. Analysis of variance or chi-square test showed that compared with non-diabetic bipolar disorder patients, diabetic bipolar disorder patients were older, more often married, had a longer duration of disease, took less olanzapine and had a higher frequency of hypertension. However, there were no significant differences in body mass index (BMI) and homocysteine levels between diabetic and non-diabetic bipolar disorder patients. Logistic regression analysis showed that marital status and duration of disease were independently associated with diabetes mellitus in patients with bipolar disorder after controlling for age, use of olanzapine, presence of hypertension, BMI and homocysteine levels. These findings shed light on the clinico-demographic correlates of the increased prevalence of diabetes mellitus in bipolar disorder patients, rather than the correlation with some metabolic risk factors.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"40 2","pages":"84-90"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spanish versions and validation of a series of rating scales and visual analogue scales to assess the subjective effects of cannabis. 西班牙语版本和一系列评定量表和视觉模拟量表的验证，以评估大麻的主观影响。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-03-01 Epub Date: 2023-11-20 DOI: 10.1097/YIC.0000000000000498

Alberto Sainz-Cort, Marta Martín-Islas, Genís Oña, Daniel Jimenez-Garrido, Miriam López-Navarro, Elena Muñoz-Marron, Raquel Viejo-Sobera, Jose Carlos Bouso

{"title":"Spanish versions and validation of a series of rating scales and visual analogue scales to assess the subjective effects of cannabis.","authors":"Alberto Sainz-Cort, Marta Martín-Islas, Genís Oña, Daniel Jimenez-Garrido, Miriam López-Navarro, Elena Muñoz-Marron, Raquel Viejo-Sobera, Jose Carlos Bouso","doi":"10.1097/YIC.0000000000000498","DOIUrl":"10.1097/YIC.0000000000000498","url":null,"abstract":"Cannabis is being legalized for medical and recreational purposes all around the world. However, the understanding of the psychological effects of cannabis is still limited, and it has been previously linked to mental disorders such as schizophrenia. Lately, new scales have been created and adapted to measure its psychological effects. The aim of this study is to create Spanish versions of some of these scales and test their psychometric characteristics. One hundred sixteen participants were recruited from Cannabis Social Clubs (CSC) in Barcelona, Spain. Participants under the effects of their own cannabis completed the Cannabis Experience Questionnaire-modified version (CEQ-mv), Addiction Research Centre Inventory-18 (ARCI-18), Psychotomimetic States Inventory (PSI) and Visual Analogue Scales (VAS). Questionnaires were completed in the CSC, providing a naturalistic setting for the study. Exploratory factor analysis and internal consistency were analyzed. PSI was reduced from a 6-factor to a 4-factor model with adequate to low reliability, ARCI-18 was reduced from a 3-factor to a 2-factor model with good reliability, and VAS were reduced from a 4-factor to a 3-factor model, also with good reliability. These questionnaires showed adequate reliability and can be used in future studies to test the subjective effects of cannabis in clinical and naturalistic settings.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"91-99"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138046808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Validation of the Spanish version of the multifaceted empathy test: comparison between cannabis use effects and controls in social cognition. 西班牙文版多方面移情测试的验证：使用大麻影响与社会认知对照组的比较。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-03-01 Epub Date: 2024-06-28 DOI: 10.1097/YIC.0000000000000544

Alberto Sainz-Cort, Marta Martín-Islas, Daniel Jimenez-Garrido, Miriam López-Navarro, Genís Oña, Elena Muñoz-Marron, Luis Heredia, Mercè Gil-Pérez, Margarita Torrente, Paloma Vicens, José Carlos Bouso

{"title":"Validation of the Spanish version of the multifaceted empathy test: comparison between cannabis use effects and controls in social cognition.","authors":"Alberto Sainz-Cort, Marta Martín-Islas, Daniel Jimenez-Garrido, Miriam López-Navarro, Genís Oña, Elena Muñoz-Marron, Luis Heredia, Mercè Gil-Pérez, Margarita Torrente, Paloma Vicens, José Carlos Bouso","doi":"10.1097/YIC.0000000000000544","DOIUrl":"10.1097/YIC.0000000000000544","url":null,"abstract":"Objective: While social cognition is shown to be impaired in several mental disorders, the effects of cannabis on social cognition are still not clear. Past studies have used the multifaceted empathy test (MET) to study social cognition. This study aims to test the validity of the MET Spanish version and to evaluate the effects of cannabis use on social cognition.Methods: In total 116 participants from a Cannabis Social Club (CSC) completed the MET and the reading the mind in the eyes test (RMET) under the effects of cannabis and were compared to 86 university students (control group). Internal consistency and convergent validity were assessed. Cognitive empathy (CE) and emotional empathy (EE) were tested in both groups.Results: The MET CE scale shows low internal consistency, while the EE scale shows high internal consistency. Items showed similar difficulty for both groups. Cannabis users showed deficient overall emotional recognition, with reduced scores associated with positive stimuli. Overall scores for EE were similar for both groups, but the experimental group scored lower with negative stimuli when compared to controls.Conclusion: This study validates the MET Spanish version for its use in future studies. Results confirmed deficient emotional recognition in cannabis users and a dampened reaction to negative stimuli for the first time.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"100-109"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141456568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expanding treatment domains across psychiatric disorders.

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-03-01 Epub Date: 2025-01-29 DOI: 10.1097/YIC.0000000000000581

Alessandro Serretti

引用次数: 0

Systematic review and network meta-analysis of agomelatine for the treatment of generalized anxiety disorder in adult patients. 阿戈美拉汀治疗成人广泛性焦虑症的系统综述和网络荟萃分析。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-03-01 Epub Date: 2024-05-20 DOI: 10.1097/YIC.0000000000000551

Sean D Hood, Olatunji Odufowora-Sita, Jean-Baptiste Briere, Marco Lucchino, Fatma Khrouf, Elzbieta Olewinska, Paulina Pierzchala, Marwa Mezghani, Mateusz Nikodem, Pierre Lévy

{"title":"Systematic review and network meta-analysis of agomelatine for the treatment of generalized anxiety disorder in adult patients.","authors":"Sean D Hood, Olatunji Odufowora-Sita, Jean-Baptiste Briere, Marco Lucchino, Fatma Khrouf, Elzbieta Olewinska, Paulina Pierzchala, Marwa Mezghani, Mateusz Nikodem, Pierre Lévy","doi":"10.1097/YIC.0000000000000551","DOIUrl":"10.1097/YIC.0000000000000551","url":null,"abstract":"This systematic literature review aimed to assess the efficacy and tolerability of agomelatine versus approved medications for the treatment of generalized anxiety disorder (GAD) in adult patients. We selected randomized controlled trials on various medications used to treat GAD in adult patients. An existing systematic literature review ( Kong et al ., 2020 ) was used to identify relevant studies published before 2020. Outcomes of remission and discontinuation due to adverse events (AEs) were analyzed, following a random-effects network meta-analysis approach. Of 25 identified studies, 20 and 22 studies were included in the network meta-analysis for studying the remission and discontinuation (due to AEs) outcomes, respectively. A statistically significant difference in the remission rate was observed between agomelatine and pregabalin [odds ratio (OR), 2.22; 95% confidence interval (CI), 1.19-4.21]. For the other comparators, the results were nonsignificant; however, all the point estimates were in favor of agomelatine. Similarly, for discontinuation because of AEs, the point estimates leaned consistently toward agomelatine suggesting its higher tolerability. The probabilities of agomelatine having the highest remission rate and lowest discontinuation (due to AEs) rate were 67% and 68%, respectively. Based on its demonstrated effectiveness and tolerability, agomelatine can be considered as a drug of choice for the treatment of GAD.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"62-74"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11781552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is Pilates effective in improving depressive disorders? A comprehensive overview. 普拉提能有效改善抑郁障碍吗？全面概述。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-03-01 Epub Date: 2024-02-29 DOI: 10.1097/YIC.0000000000000541

Francesca Legnani, Lorenzo Tassi, Teresa Surace, Enrico Capuzzi, Alice Caldiroli, Massimo Clerici, Massimiliano Buoli

{"title":"Is Pilates effective in improving depressive disorders? A comprehensive overview.","authors":"Francesca Legnani, Lorenzo Tassi, Teresa Surace, Enrico Capuzzi, Alice Caldiroli, Massimo Clerici, Massimiliano Buoli","doi":"10.1097/YIC.0000000000000541","DOIUrl":"10.1097/YIC.0000000000000541","url":null,"abstract":"Depressive disorders are disabling conditions that account for high social costs. Pilates demonstrated to have several beneficial effects on health. Objective of this manuscript was to systematically review the literature about the effects of Pilates on depressive disorders. A bibliographic search was conducted in the main database sources (Pubmed, Medline, and Scopus). The inclusion criteria consisted of articles written in English language about the effectiveness of Pilates on depressive symptoms. Most of included studies are randomized controlled trials (10 out of 12). The available literature agrees in indicating that Pilates is effective in improving depressive symptoms especially when compared to inactivity and when this practice is administered for a medium-long period (8-16 weeks). In addition, Pilates seems to have at least comparable effectiveness than aerobic exercise. Pilates can be considered a reliable complementary treatment for people with depressive disorders. These findings should be interpreted considering the different types of practice administered as well as the different duration of the programs or rating scales used to assess mood symptoms. Studies with a more homogenous design are needed to confirm and make generalizable the results presented in this review.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"53-61"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11781551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139566260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Points regarding neuroscience-based nomenclature: evaluating its impact on psychiatric residency training.

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-03-01 Epub Date: 2025-01-29 DOI: 10.1097/YIC.0000000000000561

Jeroen De Troij, Chris Bervoets

引用次数: 0

The potential use of daridorexant in eating disorders: beyond the treatment of insomnia? 达立酮在饮食失调症中的潜在用途：超越失眠治疗？

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-03-01 Epub Date: 2024-05-10 DOI: 10.1097/YIC.0000000000000552

Alice Caldiroli, Letizia M Affaticati, Enrico Capuzzi, Davide La Tegola, Fabrizia Colmegna, Massimo Clerici, Antonios Dakanalis, Massimiliano Buoli

{"title":"The potential use of daridorexant in eating disorders: beyond the treatment of insomnia?","authors":"Alice Caldiroli, Letizia M Affaticati, Enrico Capuzzi, Davide La Tegola, Fabrizia Colmegna, Massimo Clerici, Antonios Dakanalis, Massimiliano Buoli","doi":"10.1097/YIC.0000000000000552","DOIUrl":"10.1097/YIC.0000000000000552","url":null,"abstract":"A strong interplay exists between sleep and dietary habits, and sleep disturbances have been repeatedly documented in individuals with eating disorders (EDs). The orexin system - implicated in sleep regulation, energy homeostasis, and food reward - may represent a mechanist link between sleep alterations and disordered eating behaviors. Daridorexant is a dual orexin receptor antagonist (DORA) recently approved for the treatment of insomnia, with demonstrated efficacy and tolerability. Owing to its action on orexin neurons, the compound represents an intriguing option for addressing both sleep-related and core symptoms of EDs. By inhibiting motor hyperactivity, daridorexant may reduce excessive physical exercise in individuals with anorexia nervosa (AN) restricting type. Additionally, the compound may exert anti-binge effects, suggesting broad applicability in binge ED, bulimia nervosa, and binge/purging AN. In this framework, daridorexant emerges as a promising therapeutic option, offering a multifaceted approach to improving circadian rhythms, energy balance, and overall quality of life in individuals with diverse ED subtypes.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"115-118"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differentiating aspects of oral and long-acting injectable antipsychotic drugs for tailoring the therapy of schizophrenia in clinical practice: a narrative review. 在临床实践中区分口服和长效注射抗精神病药物对精神分裂症治疗的影响：一篇叙述性综述。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-01-22 DOI: 10.1097/YIC.0000000000000578

Andrea Fagiolini, Alessandro Cuomo, Domenico De Berardis, Bernardo Dell'Osso, Maurizio Pompili, Gianluca Serafini

{"title":"Differentiating aspects of oral and long-acting injectable antipsychotic drugs for tailoring the therapy of schizophrenia in clinical practice: a narrative review.","authors":"Andrea Fagiolini, Alessandro Cuomo, Domenico De Berardis, Bernardo Dell'Osso, Maurizio Pompili, Gianluca Serafini","doi":"10.1097/YIC.0000000000000578","DOIUrl":"https://doi.org/10.1097/YIC.0000000000000578","url":null,"abstract":"Schizophrenia is a serious psychiatric condition requiring continuous treatment with antipsychotic medications available in different formulations, including oral antipsychotics (OAPs) and long-acting injectables (LAIs). This narrative review aims to comprehensively outline the advantages and disadvantages of OAPs and LAIs to support clinicians in choosing different formulations based on the presentation of clinical symptoms. An electronic search of the PubMed database was performed in June 2024, and additional articles were retrieved from the references or personal knowledge of the authors. Relevant advantages of OAPs identified in the literature include dosing flexibility, ease of discontinuation, lower cost, autonomy of patient administration, shorter time to steady-state, and wide choice of molecules, including risk of nonadherence, plasma level fluctuations, food and drug interactions, and polypharmacy. LAIs' advantages include improved adherence leading to reduced relapse rates and hospitalizations, patient convenience, and stable drug levels while disadvantages include discomfort of injection, possible stigma, less manageable drug interactions, organization of administration centers, and patient preference possibly contrary to physician preference. When treating schizophrenia, it is critical to consider patients' needs, preferences, and history of medication adherence. Combining patient education with individualized treatment plans may optimize outcomes and improve the quality of life.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intravenous trazodone for the treatment of psychomotor agitation and associated symptoms in major depressive disorder patients experiencing a depressive episode with mixed features. 静脉曲唑酮治疗伴有混合特征的抑郁发作的重度抑郁症患者的精神运动性躁动及相关症状

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-01-13 DOI: 10.1097/YIC.0000000000000580

Pietro Carmellini, Alessandro Cuomo, Caterina Pierini, Simone Pardossi, Mario Pinzi, Elisa Mariantoni, Andrea Fagiolini

{"title":"Intravenous trazodone for the treatment of psychomotor agitation and associated symptoms in major depressive disorder patients experiencing a depressive episode with mixed features.","authors":"Pietro Carmellini, Alessandro Cuomo, Caterina Pierini, Simone Pardossi, Mario Pinzi, Elisa Mariantoni, Andrea Fagiolini","doi":"10.1097/YIC.0000000000000580","DOIUrl":"https://doi.org/10.1097/YIC.0000000000000580","url":null,"abstract":"Psychomotor agitation is a challenging symptom of major depressive disorder with mixed features (MDD-MF), often worsening outcomes and complicating treatment. This retrospective study assessed the efficacy and tolerability of intravenous trazodone in 97 hospitalized patients with MDE-MF. Symptom severity was evaluated using montgomery asberg depression rating Scale (MADRS), young mania rating scale, hamilton anxiety rating scale, GAD-7, and clinical global impression scale-severity of illness (CGI-S) scales, with significant reductions in agitation, anxiety, and irritability observed early during treatment. Correlation analyses revealed significant negative associations between intravenous (IV) trazodone dosage and improvements in MADRS (r = -0.23; P < 0.05), item 5 of GAD-7 (r = -0.27; P < 0.001), and CGI-S scores (r = -0.22; P < 0.05). Therapy duration also correlated negatively with improvements in GAD-7 item 5 (r = -0.29; P < 0.001) and CGI-S (r = -0.27; P < 0.001), indicating diminishing returns with prolonged treatment. Regression analyses showed that therapy duration, but not dosage, significantly influenced improvements in GAD-7 item 5 and CGI-S. Trazodone was well-tolerated, with only mild side effects in 11.3% of patients. These findings suggest that IV trazodone effectively reduces agitation and related symptoms in MDD-MF, particularly in the early treatment phase, emphasizing the importance of optimizing treatment duration. Future studies should investigate individualized dosing strategies and explore long-term outcomes in this population.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143004954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0